secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moringa Acquisition Corp (—)
CIK:        0001835416
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001213900-24-016967
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moringa Acquisition Corp signs definitive merger with Silexion at $62.5M valuation
--------------------------------------------------------------------------------

- SPAC Moringa (MACA) enters Business Combination Agreement with Israeli oncology firm Silexion Therapeutics; pre-transaction equity value $62.5M.
- SPAC sponsor to forfeit 1,567,000 founder shares; closing requires minimum unrestricted cash of $500K.
- Silexion must deliver at least $3.5M in convertible loan financing proceeds by March 10, 2024, as a closing condition.
- Transaction must close by August 19, 2024; no termination fees payable by either party.
- Silexion is a clinical-stage biotech developing therapies for KRAS-mutant solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/0001213900-24-016967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/ea0200686-8k_moringa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-016967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer